Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well sorafenib tosylate works in treating
patients with liver cancer that can be removed by surgery.
Phase:
Phase 2
Details
Lead Sponsor:
GERCOR - Multidisciplinary Oncology Cooperative Group Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)